Drugs / PrimeMSK™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04684602 | Jul 2020 → Jul 2030 expected | autoimmune disease, cardiovascular disorder, integumentary system disorder, lung disorder +5 | Thomas Advanced Medical LLC | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PrimeMSK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04684602 ↗ |